Rethinking clinical trial endpoints in myelodysplastic syndromes. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes |
Jun 2024 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study |
Jul 2020 |
Leukemia Research |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS) |
Jan 2021 |
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) |
Mar 2021 |
Cancers |
Chronic Myelomonocytic Leukaemia (CMML), Myelodysplastic Syndromes (MDS) |
Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review |
Jul 2023 |
Experimental Hematology & Oncology |
Myelodysplastic Syndromes (MDS) |
Romiplostim for Treatment of Children and Young Adults With Severe Aplastic Anemia and Myelodysplastic Syndrome |
May 2024 |
Journal of Pediatric Hematology/Oncology |
Aplastic Anemia |
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial |
Jan 2024 |
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |